Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374956 · ClinicalTrials.gov registry record · Phase 3
Individualized Obesity Pharmacotherapy
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT03374956: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT03374956 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 193 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03374956, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.
Interventions
- DRUG Liraglutide
- DRUG Phentermine-Topiramate
- DRUG Phentermine
- DRUG Naltrexone/bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2022-05-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03374956
The ClinicalTrials.gov registry entry for NCT03374956 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Liraglutide is the first listed.
NCT03374956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03374956 about?
NCT03374956 is a clinical study titled "Individualized Obesity Pharmacotherapy". The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.
What is the current status of trial NCT03374956?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2017-12-11. Estimated completion is 2022-05-26.
What interventions are being tested in trial NCT03374956?
The interventions under investigation include: Liraglutide (DRUG), Phentermine-Topiramate (DRUG), Phentermine (DRUG), Naltrexone/bupropion (DRUG).
Who is sponsoring clinical trial NCT03374956?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.